Targeting Hepatitis B Virus DNA Using Designer Gene Editors

Clin Liver Dis. 2023 Nov;27(4):895-916. doi: 10.1016/j.cld.2023.05.006. Epub 2023 Jul 4.

Abstract

Chronic hepatitis B virus (HBV) infection is a serious disease that currently has no cure. Key forms of HBV include covalently closed circular DNA, which mediates chronic persistence, and integrated DNA, which contributes to immune evasion and carcinogenesis. These forms are not targeted by current therapies; however, gene editing technologies have emerged as promising tools for disrupting HBV DNA. Gene editor-induced double-stranded breaks at precise locations within the HBV genome can induce effects ranging from inactivation of target genes to complete degradation of the target genome. Although promising, several challenges remain in efficacy and safety that require solutions.

Keywords: CRISPR-Cas9; Hepatitis B virus; Integrated DNA; TALEN; ZFN; cccDNA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CRISPR-Cas Systems
  • DNA, Circular / genetics
  • DNA, Circular / metabolism
  • DNA, Circular / pharmacology
  • DNA, Viral / genetics
  • Hepatitis B virus* / genetics
  • Hepatitis B*
  • Hepatitis B, Chronic* / therapy
  • Humans
  • Virus Replication

Substances

  • DNA, Circular
  • DNA, Viral